{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:22:47Z","timestamp":1787851367568,"version":"build-2784847793"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006928","name":"Ohio State University","doi-asserted-by":"publisher","award":["startup funds"],"award-info":[{"award-number":["startup funds"]}],"id":[{"id":"10.13039\/100006928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["postdoctoral fellowship award"],"award-info":[{"award-number":["postdoctoral fellowship award"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013699","name":"The Ohio State University OSUCCC \u2013 James","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","award":["Recruitment Startup Fund"],"award-info":[{"award-number":["Recruitment Startup Fund"]}],"id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011619","name":"Society for Immunotherapy of Cancer","doi-asserted-by":"publisher","award":["Single Cell Biology Award"],"award-info":[{"award-number":["Single Cell Biology Award"]}],"id":[{"id":"10.13039\/100011619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108300","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:34:08Z","timestamp":1785414848000},"page":"108300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Era-specific prognostic factors and an interpretable machine-learning survival model for renal cell carcinoma brain metastases"],"prefix":"10.1016","volume":"11","author":[{"given":"S.","family":"Ozgul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9675-9287","authenticated-orcid":false,"given":"Z.F.","family":"Akpinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Suki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Acikgoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jonasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7195-0842","authenticated-orcid":false,"given":"M.","family":"Hasanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hasanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2026.108300_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108300_bib2","first-page":"454","article-title":"An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma","volume":"72","author":"Hasanov","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108300_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/PPO.0000000000000471","article-title":"The immunotherapy revolution in kidney cancer treatment: scientific rationale and first-generation results","volume":"26","author":"Hasanov","year":"2020","journal-title":"Cancer J"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108300_bib4","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.esmoop.2026.108300_bib5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.687","article-title":"Evaluation of brain metastasis in JAVELIN Renal 101: efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S)","volume":"38","author":"Jonasch","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108300_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/bju.16148","article-title":"Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy","volume":"133","author":"Castro","year":"2024","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108300_bib7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.hoc.2023.04.020","article-title":"Management of brain metastases in metastatic renal cell carcinoma","volume":"37","author":"Hasanov","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108300_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108300_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101598","article-title":"An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study","volume":"8","author":"Intern\u00f2","year":"2023","journal-title":"ESMO Open"},{"issue":"Suppl 2","key":"10.1016\/j.esmoop.2026.108300_bib10","doi-asserted-by":"crossref","first-page":"S587","DOI":"10.4103\/jcrt.jcrt_972_22","article-title":"Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases","volume":"19","author":"Dogan","year":"2023","journal-title":"J Cancer Res Ther"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108300_bib11","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ijrobp.2018.04.006","article-title":"Effect of targeted therapies on prognostic factors, patterns of care, and survival in patients with renal cell carcinoma and brain metastases","volume":"101","author":"Sperduto","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108300_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41416-021-01633-1","article-title":"Artificial intelligence in oncology: current applications and future perspectives","volume":"126","author":"Luchini","year":"2022","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108300_bib13","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2021-0074","article-title":"An overview of artificial intelligence in oncology","volume":"8","author":"Farina","year":"2022","journal-title":"Future Sci OA"},{"key":"10.1016\/j.esmoop.2026.108300_bib15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/B978-0-12-811161-1.00007-4","article-title":"Brain metastases: neuroimaging","volume":"149","author":"Pope","year":"2018","journal-title":"Handb Clin Neurol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108300_bib16","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108300_bib17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.esmoop.2026.108300_bib18","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108300_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/PPO.0000000000000754","article-title":"Effective personalization of stereotactic radiosurgery for brain metastases in the modern era: opportunities for innovation","volume":"30","author":"Edwards","year":"2024","journal-title":"Cancer J"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108300_bib20","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0360-3016(01)01622-4","article-title":"Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method","volume":"51","author":"Sanghavi","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108300_bib21","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2024.01.006","article-title":"Outcomes of patients with brain metastases from renal cell carcinoma receiving first-line therapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"86","author":"Takemura","year":"2024","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108300_bib22","doi-asserted-by":"crossref","first-page":"e1163","DOI":"10.1016\/j.clgc.2019.08.006","article-title":"Brain metastasis from renal-cell carcinoma: an institutional study","volume":"17","author":"Suarez-Sarmiento","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"13","key":"10.1016\/j.esmoop.2026.108300_bib23","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3390\/cancers14133127","article-title":"RCC real-world data: prognostic factors and risk stratification in the immunotherapy era","volume":"14","author":"Sagie","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:33:04Z","timestamp":1787848384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926022428"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108300","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Era-specific prognostic factors and an interpretable machine-learning survival model for renal cell carcinoma brain metastases","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108300"}}